All Stories

  1. Building bridges for early-career rheumatologists in Türkiye: insights from the Turkish Society for Rheumatology—Young Rheumatologists
  2. The joint-local renin–angiotensin system in rheumatoid arthritis and osteoarthritis: mechanistic evidence, disease-specific patterns, and translational perspectives
  3. The Risk of Developing Ocular Involvement Among Behçet’s Disease Patients Presenting with Mucocutaneous Involvement at Disease Onset: Data from the International AIDA Network Behçet’s Disease Registry
  4. Sleep quality and blood pressure variability after anti-TNF-α treatment in axial spondyloarthritis patients: A prospective preliminary study
  5. Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions
  6. Educational and skill development needs of early-career rheumatologists in Türkiye
  7. Central nervous system demyelination associated with biological agents used in the treatment of rheumatologic diseases: a retrospective cohort study
  8. Behçet's disease beyond the criteria: insights from a tertiary centre in Turkey
  9. Measuring what matters! The role of AAV-PRO in patient-centered care for EGPA: insights from the study by Delvino et al.
  10. Current application, possibilities, and challenges of artificial intelligence in the management of rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis
  11. QuantiFERON-TB Gold Plus for screening and monitoring latent tuberculosis infection in spondyloarthritis patients
  12. From Conventional to Advanced Therapies: A National Health Registry Report (2016-2022) on DMARDs in Rheumatoid Arthritis Treatment in Turkey
  13. Exploring the 'risk': Comments on the FAERS data regarding the safety of JAK inhibitors by Mikaeili et al.
  14. Comments on the article by Goldman et al.
  15. Beyond being a rheumatologist: Environment, climate change, and carbon footprint – We need an action!
  16. ACPA is a main risk factor for CT-proven pulmonary nodule progression in patients with rheumatoid arthritis
  17. Ethical challenges and regulatory pathways for artificial intelligence in rheumatology
  18. Comments and perspectives on the TREAT EARLIER study
  19. Prevalence, incidence and geographic distribution of familial Mediterranean fever in Turkey: a national cohort study
  20. A nationwide study: prevalence of rheumatoid factor and anti- citrullinated peptide positivity and their contribution to rheumatoid arthritis diagnosis
  21. Correction: Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS)
  22. Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS)
  23. Unveiling Cancer Risk in ANCA-Associated Vasculitis: Result from the Turkish Vasculitis Study  Group (TRVaS)
  24. Comment on: AI am a rheumatologist: a practical primer to large language models for rheumatologists. Second reply
  25. Craniocervical junction involvement in inflammatory arthritis: a single-center radiologic study
  26. Factors that predict development of chronic kidney disease in patients with rheumatoid arthritis receiving biologic DMARDs and mortality rates
  27. Adapting HUVAC Vasculitis Registry to a Country-wide online registry system: Turkish Vasculitis Study Group Prospective Database, TRVaS
  28. Costovertebral and costotransverse joint involvement in spondyloarthritis
  29. Comment on: AI am a rheumatologist: a practical primer to large language models for rheumatologists: reply
  30. The predictors of paradoxical reactions, especially psoriasis, to biologic therapy—findings from the TReasure database: a 5-year follow-up study
  31. AI am a rheumatologist: a practical primer to large language models for rheumatologists
  32. Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry
  33. Do the drug doses of conventional synthetic DMARDs used for the treatment of biologic/targeted-synthetic DMARDs naive rheumatoid arthritis patients affect QuantiFERON-TB Gold Plus test results?
  34. Comparison of lupus nephritis and non-lupus nephritides in patients with systemic lupus erythematosus
  35. Derivation and validation of adult Still Activity Score (SAS)
  36. Comparison of demographic, clinic and radiological features of patients with axial spondyloarthritis accompanying familial Mediterranean fever to patients with each condition alone
  37. Epidemiological characteristics of hepatitis B and C in patients with inflammatory arthritis: Implications from treasure database
  38. Autoinflammation in psoriatic arthritis: time to better define the multifaceted enemy
  39. Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis
  40. Predicting the response to bDMARD treatment in RA: Then what?
  41. Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: Single centre, cross-disciplinary experience
  42. Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study
  43. Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results
  44. Extremely high erythrocyte sedimentation rate revisited in rheumatic diseases: a singlecenter experience
  45. Can we predict transition from psoriasis to psoriatic arthritis?
  46. The influence of obesity on biological agents treatment response in psoriatic arthritis: HUR-BIO real life results
  47. From asymptomatic to critical illness: decoding various clinical stages of COVID-19
  48. Conventional Synthetic Dmards in Psoriatic Arthritis: Changing Practice in Biologic Era; Real-Life Results from HURBIO-PsA Registry
  49. The clinical features and treatment of eosinophilic granulomatosis with polyangiitis (EGPA) in Turkey: one or two distinct diseases?
  50. Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data
  51. Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data
  52. The frequency of Achilles and plantar calcaneal spurs in gout patients
  53. Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
  54. c-ANCA positivity in a patient with relapsing polychondritis: Co-incidence or not? A case and review of the literature
  55. In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?
  56. Iliac artery aneurysm in Behçet’s syndrome: collaborative management is essential
  57. Journey of Vasculitis at Hacettepe University: from the Establishment of University to the Hacettepe AAV Workshop, 2020
  58. Successful treatment of penile Mondor’s disease with infliximab in a patient with Behçet’s disease
  59. Association of disease characteristics with the temporal sequence of skin and musculoskeletal disease onset in psoriatic arthritis
  60. Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience
  61. PILE: a candidate prognostic score in cancer patients treated with immunotherapy
  62. Proposal of a new nomenclature for the underlying pathogenetic mechanism of severe Coronavirus Disease-19: “Inflammatory Thrombosis with Immune Endotheliitis—ITIE”
  63. Mediastinal mass in a patient with rheumatoid arthritis: lymphoid cystic thymic hyperplasia
  64. Clinical Characteristics and Outcome of ANCA-Associated Vasculitis; Experience of A Single Reference Vasculitis Center
  65. Spinal and cerebral hematoma in systemic lupus erythematosus and antiphospholipid syndrome: is drug interaction the culprit?
  66. Treatment modalities in psoriatic arthritis
  67. Geoepidemiology and clinical characteristics of neonatal lupus erythematosus: a systematic literature review of individual patients’ data
  68. Temporomandibular disorders in ankylosing spondylitis: a cross-sectional, monocentric study
  69. Histopathological subgrouping versus renal risk score for the prediction of end-stage renal disease in ANCA-associated vasculitis
  70. Comparison of Diagnostic Subgroup Survivals of Patients Who Admitted for Fever of Unknown Etiology Evaluation: Long-term Results of Single-centre, Prospective Study
  71. Influenza epidemiology and influenza vaccine effectiveness during the 2016–2017 season in the Global Influenza Hospital Surveillance Network (GIHSN)
  72. Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia
  73. Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial
  74. Correction to: Proposal for a simple algorithm to differentiate adult-onset Still’s disease with other fever of unknown origin causes: a longitudinal prospective study
  75. Proposal for a simple algorithm to differentiate adult-onset Still’s disease with other fever of unknown origin causes: a longitudinal prospective study
  76. Some concerns from Turkey
  77. Remission of relapsing polychondritis after successful treatment of myelodysplastic syndrome with azacitidine: a case and review of the literature
  78. Blood group ‘A’ may have a possible modifier effect on familial Mediterranean fever and blood group ‘0’ may be associated with colchicine resistance
  79. Aspergillus Pneumonia in a Patient With Adult-Onset Still Disease Successfully Treated With Anakinra
  80. Familial Mediterranean fever: New insights into cancer immunoprevention?
  81. Increased psoriasis frequency in patients with familial Mediterranean fever
  82. The association of various social capital indicators and physical activity participation among Turkish adolescents
  83. Poor outcomes among elderly patients hospitalized for influenza-like illness
  84. Increased cancer risk in patients with periodontitis
  85. Comparing polyarteritis nodosa in children and adults: a single center study
  86. Amniotic Membrane Transplantation for Spontaneous Corneal Perforation in a Case Of Rheumatoid Arthritis
  87. Behçet Disease With Vascular Involvement